Funding secured for the first clinical study of BioC wound gel

A rights issue has been completed and successfully raised 14.5 million SEK for Xinnate to fund the first clinical study of BioC wound gel. We plan to begin the study in the fourth quarter of 2021 and will evaluate the safety and antimicrobial and anti-inflammatory effects of BioC in wounds.

Xinnate has received a prestigious Swedish Research Council grant

Xinnate co-founder Artur Schmidtchen has received 9.5 MSEK in funding from the Swedish Research Council – the largest grant awarded in the field of medicine in this round. The application received the highest possible rating in all assessment categories. The money will go to in-depth basic research on mechanisms related to wound healing, which will be commercialized by Xinnate.